Significant Analysis of Microarray (SAM) to Identify Synergistic Effect of RV and NGF in Repairing Damaged Neuronal Cells


  • Amity University Uttar Pradesh, Lucknow Campus, Amity Institute of Biotechnology, Lucknow, Uttar Pradesh, 226028, India


Neurodevelopmental disorders include diseases that are related with genetic disorders and are caused due to stress condition or environmental toxins during pre or post natal condition. In recent years, there is considerable research in neurodevelopmental disorders and examining therapeutic role of resveratrol as potential antioxidant. There is less information about the genes that are mutated or altered during neurodevelopmental phase and cause neuronal developmental disorders. Current researches are evidentially showing the therapeutic potential of Resveratrol (RV) and Nerve Growth Factor (NGF) against neuronal diseases. In current study Microarray experiment was designed to identify the genes that are altered when Mesenchymal Stem Cells (MSC) were exposed to Monocrotophos (MCP). MSCs were also coexposed with resveratrol and nerve growth factor to study the synergistic effect of NGF with RV. Computational analysis of microarray data was carried out through different software’s and bioinformatics tools to identify genes that are expressed in different samples across microarray experiment. Statistical methods like T-test, SAM analysis and clustering techniques were performed between different samples using MeV software. Through Significant Analysis of Microarray (SAM) method we identified positive and negative significant genes with respect to current study. Clustering method was used to cluster genes associated with neuronal disease genes. Key genes that were predicted on the basis of t-test and SAM analysis are DNMT1, PGAP1, RDX and PEX26 genes, these genes have noticeable function in different classes of neuronal diseases like cerebellar ataxia, deafness, narcolepsy, mental retardation and zellweger spectrum disorder etc. Cluster analysis we identified genes such as ATP6V0D1, TESMIN, TRIM22, NAPEPLD, CDK7 and PKM, these genes have important function in cell growth, cell proliferation, protein synthesis, cell cycle regulation, and cell signaling. Study suggests that exposure of damaged neuronal cells to RV and NGF enhances the expression of neuronal repair genes, thus signifies the neuroprotectant and synergistic activity of RV and NGF. “The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus database and are accessible through GEO Series accession number GSE121261 (”


Microarray Analysis, Nerve Growth Factor, Neuronal Damage, Neuronal Diseases, Resveratrol, SAM.

Subject Discipline


Full Text:


Levi-Montalcini R. The nerve growth factor 35 years later. Science. 1987; 237: 1154–62. PMid:3306916

Schmidt CE, Leach JB. Neural tissue engineering: strategies for repair and regeneration. Annual Review of Biomedical Engineering. 2003; 5: 293–347. PMid:14527315

Bradshaw RA. Nerve growth factor. Annual Review of Biochemistry. 1978; 47: 191–216. PMid:79332

Sofroniew MV, Charles LH, William CM. Nerve growth factor signaling, neuroprotection, and neural repair. Annual Review of Neuroscience. 2001; 24: 1217–81. PMid:11520933

Shigeno T, et al. Amelioration of delayed neuronal death in the hippocampus by nerve growth factor. Journal of Neuroscience. 1991; 11(9): 2914–9. PMid:1880556

Pfister LA, et al. Nerve conduits and growth factor deliveryi n peripheral nerve repair. Journal of the Peripheral NervousSystem. 2007; 12(2): 65–82. PMid:17565531

Rich KM, et al. Nerve growth factor enhances regeneration through silicone chambers. Experimental Neurology. 1989; 105(2): 162–70.

Schwab ME. Repairing the injured spinal cord. Science. 2002; 295(5557): 1029–31. PMid:11834824

Fawcett JW, Richard AA. The glial scar and central nervoussystem repair. Brain Research Bulletin. 1999; 49: 377–91.

Hefti F, William JW. Nerve growth factor and Alzheimer’s disease. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1986; 20: 275–81.

Fahnestock M, et al. The precursor pro-nerve growth factoris the predominant form of nerve growth factor in brain and is increased in Alzheimer’s disease. Molecular and Cellular Neuroscience. 2001; 18: 210–20. PMid:11520181

Siemann EH, Creasy LL. Concentration of the phytoalex in resveratrol in wine. American Journal of Enology and Viticulture. 1992; 43: 49–52.

Baur JA, David AS. Therapeutic potential of resveratrol: thein vivo evidence. Nature Reviews Drug discovery. 2006; 5:493. PMid:16732220

Robb EL, Jeffrey AS. Trans-resveratrol as a neuroprotectant. Molecules. 2010; 15: 1196–212. PMid:20335973 PMCid:PMC6257315

Granzotto A, Zatta P. Resveratrol and Alzheimer’s disease:message in a bottle on red wine and cognition. Frontiers inAging Neuroscience. 2014; 6: 95. PMid:24860502 PMCid:PMC4030174

Ding X-Z, Thomas EA. Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas. 2002; 25: 71–6.

Reddy NCS, Karnati PR. Protective effect of resveratrolagainst neuronal damage through oxidative stress incerebral hemisphere of aluminum and fluoride treated rats. Interdisciplinary Toxicology. 2016; 9: 78–82. PMid:28652849PMCid:PMC5458107

Baxter RA. Anti‐aging properties of resveratrol: review and report of a potent new antioxidant skin care formulation. Journal of Cosmetic dermatology. 2008; 7: 2–7. PMid:18254804

Zhang L-N, et al. Neuroprotective effect of resveratrol against glutamate-induced excitotoxicity. Adv Clin ExpMed. 2015; 24: 161–5.

Meftahi G, et al. Suppressive effects of resveratroltreatment on the intrinsic evoked excitability of CA1 pyramidalneurons. Cell Journal. 2015; 17: 532. PMid:26464825PMCid:PMC4601874

Saleh, MC, et al. Co-administration of resveratrol andlipoic acid, or their synthetic combination, enhances neuroprotection in a rat model of ischemia/reperfusion. PloS One. 2014; 9: 87865. PMid:24498217 PMCid:PMC3909267

Frémont L. Biological effects of resveratrol. Life Sciences. 2000; 66: 663–73.

Siemann EH, Creasy LL. Concentration of the phytoalex in resveratrol in wine. American Journal of Enology and Viticulture. 1992; 43: 49–52.

Mirnics K, et al. Analysis of complex brain disorders withgene expression microarrays: Schizophrenia as a disease of the synapse. Trends in Neurosciences. 2001; 24: 479–86.

Mirnics K, Pevsner J. Progress in the use of microarraytechnology to study the neurobiology of disease. Nature Neuroscience. 2004; 7: 434.

Boccuto L, et al. Decreased tryptophan metabolism inpatients with autism spectrum disorders. MolecularAutism. 2013; 4: 16. PMid:23731516 PMCid:PMC3680090

Brazma A, et al. Array Express- a public repository for microarray gene expression data at the EBI. Nucleic Acids Research. 2003; 31: 68–71. PMid:12519949 PMCid:PMC165538

Edgar R, Domrachev M, Lash AE. Gene expression omni bus: NCBI gene expression and hybridization array data repository. Nucleic Acids Research. 2002; 30: 207–10.

Chahrour M, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008; 320: 1224–9. PMCid:PMC2443785

Ishigaki S, et al. Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords–screeningby molecular indexing and subsequent cDNA microarrayanalysis. FEBS Letters. 2002; 531: 354–8.

Mullighan CG. The molecular genetic makeup of acutelymphoblastic leukemia. ASH Education Program Book. 2012; 2012: 389–96.

Freeman T. High throughput gene expression screening:its emerging role in drug discovery. Medicinal Research Reviews. 2000; 20: 197–202.<197::AIDMED3>3.0.CO;2-1

Yadav R, Srivastava P. Clustering, pathway enrichment,and protein-protein interaction analysis of gene expression in neurodevelopmental disorders. Advances in Pharmacological Sciences. 2018; 2018.

Smyth GK, Yang YH, Speed T. Statistical issues in cDNAmicroarray data analysis. Functional Genomics. 2003;224: 111036.

Durinck S, et al. Bio Mart and Bioconductor: A powerfullink between biological databases and microarray dataanalysis. Bioinformatics. 2005; 21: 3439–40. https://doi. org/10.1093/bioinformatics/bti525 PMid:16082012

Saeed AI, et al. TM4 microarray software suite. Methods in Enzymology. 2006; 411: 134–93.

Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37: 13.

Baldi P, Long AD. A Bayesian framework for the analysis ofmicroarray expression data: Regularized t-test and statistical inferences of gene changes. Bioinformatics. 2001; 17:509–19.

Dinu I, et al. Improving gene set analysis of microarraydata by SAM-GS. BMC Bioinformatics. 2007; 8: 242. PMid:17612399PMCid:PMC1931607

Cheadle C, et al. Analysis of microarray data using Z score transformation. The Journal of Molecular Diagnostics. 2003;5: 73–81.

Cahan P, et al. Meta-analysis of microarray results: challenges, opportunities, and recommendations for standardization. Gene. 2007; 401: 12–8. PMid:17651921 PMCid:PMC2111172

Butte A. The use and analysis of microarray data. NatureReviews Drug discovery. 2002; 1: 951. PMid:12461517

Feng J, et al. Dnmt1 and Dnmt3a maintain DNA methylationand regulate synaptic function in adult forebrain neurons. Nature Neuroscience. 2010; 13: 423. PMid:20228804 PMCid:PMC3060772

Liu L, etal. DNA methylation impacts on learning and memory inaging. Neurobiology of Aging. 2009; 30: 549–60. PMid:17850924PMCid:PMC2656583

Novarino G, et al. Exome sequencing links corticospinalmotor neuron disease to common neurodegenerative disorders. Science. 2014; 343: 506–11. PMid:24482476 PMCid:PMC4157572

Benitez-King G, et al. The neuronal cytoskeleton as apotential therapeutical target in neurodegenerative diseases and schizophrenia. Current Drug Targets-CNS and Neurological Disorders. 2004; 3: 515–33. PMid:15581421

Fujiki Y, Yagita Y, Matsuzaki T. Peroxisome biogenesis disorders:Molecular basis for impaired peroxisomal membraneassembly: in metabolic functions and biogenesis of peroxisomesin health and disease. Biochimica et Biophysica Acta(BBA)-Molecular Basis of Disease. 2012; 1822: 42.

Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Medicine. 1997; 3: 614. PMid:9176486

Myrie KA, et al. Mutation and expression analysis of human BUB1 and BUB1B in aneuploid breast cancer cell lines. Cancer Letters. 2000; 152: 193–9.

Meech R, et al. A novel function for UDP Glycosyl transferase 8 (UGT8): Galactosidation of bile acids. Molecular Pharmacology. 2015; 87(3): 442–50. PMid:25519837

Cuevas R, et al. FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57. Cancer Research. 2013 Feb 15; 73(4): 1400–10. PMid:23243019

Moosmang S, et al. Cellular expression and functional characterization of four hyperpolarization‐activated pacemaker channels in cardiac and neuronal tissues. European Journal of Biochemistry. 2001; 268: 1646–52. PMid:11248683

Hoffmann K et al. Mutations in the gene encoding the lamin B receptor produces an altered nuclear morphology in granulocytes (Pelger–Huet anomaly). Nature Genetics. 2002;31: 410.

Marion V, et al. Exome sequencing identifies mutationsin LZTFL1, a BB Some and smoothened trafficking regulator,in a family with Bardet–Biedl syndrome with situs in versus and insertional polydactyly. Journal of Medical Genetics. 2012; 49: 317–21. PMid:22510444

Liu N-P, et al. Mutations in corneal carbohydrate sulfotransferase 6 gene (CHST6) cause macular corneal dystrophy inI celand. 2000 Dec 13; 6: 261–4.

Flück CE, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixlersyndrome. Nature Genetics. 2004 Mar; 36(3): 228–30.

Tanaka K, et al. Analysis of a human DNA excision repairgene involved in group Axeroderma pigmentosum andcontaining a zinc-finger domain. Nature 1990; 348: 73.

Hallstrand TS, et al. Secreted phospholipase A2 group X overexpression in asthma and bronchial hyperresponsiveness. American Journal of Respiratory and Critical Care Medicine. 2007; 176: 1072–8. PMid:17901411 PMCid:PMC2176098

Zoncu R, et al. mTORC1 senses lysosomal amino acidsthrough an inside-out mechanism that requires the vacuolar H+-ATPase. Science. 2011; 334: 678–83. PMid:22053050PMCid:PMC3211112

Yu S, et al. Identification of tripartite motif-containing 22(TRIM22) as a novel NF-κB activator. Biochemical and Biophysical Research Communications. 2011; 410: 247–51. PMid:21651891

Okamoto Y, et al. Molecular characterization of a phospholipase D generating an andamide and its congeners. Journal of Biological Chemistry. 2004; 279: 5298–305. PMid:14634025

Pendergast AM, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993; 75: 175–85.

Wei Q, et al. Tumor-suppressive functions of leucine zippertranscription factor–like 1. Cancer Research. 2010; 0008:5472.

Bajorek, M, et al. Structural basis for ESCRT-III protein auto inhibition. Nature Structural and Molecular Biology. 2009;16: 754.

Chen S, Wang J, Siegelbaum SA. Properties of hyperpolarizationactivated pacemaker current defined by coassembly of HCN1 and HCN2 subunits and basal modulation bycyclic nucleotide. The Journal of General Physiology. 2001;117: 491–504. PMCid:PMC2233656

Wu K, et al. Expression of neuronal protein synucleingamma gene as a novel marker for breast cancer prognosis. Breast Cancer Research and Treatment. 2007; 101:259–67.


  • There are currently no refbacks.